the validated, Canadian risk scoring model were sensitive to the resulting variation in RSV-related hospitalization rates. In instances where risk was low, palivizumab was not cost-effective. However, for infants with at least moderate risk (2 or more risk factors), palivizumab had incremental costs per QALY that indicated moderate to strong evidence for adoption (range: $1,598 to $30,819 per QALY). CONCLUSION: Palivizumab was costeffective and our model supports prophylaxis for infants born at 32 to 35 weeks GA, particularly those with moderate risk of RSV.
Gauvreau CL University of Toronto, Toronto, ON, Canada To make appropriate use of the growing economic evidence base in health care, developing countries need applications relevant to their own national health objectives. One objective is protection for individuals and governments against the financial risks of ill health, more critical in low-resource settings. Yet, advancements in cost-effectiveness analysis (CEA) have not focused on the importance of efficiency in contributing to this goal. The lowest income nations also rely heavily on external funds from donor countries and organizations. While the recent emergence of non-traditional donors has greatly increased funding levels for global health, the large scale, narrow focus and time limitations of some of the funding have also raised questions of their effects on national health priorities as well as on the opportunity costs of the interventions supported by this funding. In attaining efficiency with a view towards minimizing financial risk, CEA must address two issues in this case: that the additional resources are efficiently allocated and that the resources themselves are not a source of financial risk. This doctoral project proposes a conceptual framework for a CEA "reference case" in the broader context of health financing in developing countries. Suggested modifications of the prevailing reference cases are literature-based, iteratively guided by key informants. Costing and sensitivity analysis with respect to external funding are highlighted. An application to the introduction of rotavirus immunization illustrates the framework. The conceptual framework anticipates the imminent introduction of expensive new vaccines targeted at resource-poor, donordependant health systems. It allows analysts and policy-makers to harmonize efficiency and financial risk objectives. It also helps donors in assessing aid effectiveness of assisted programs. Ultimately, this framework improves the transferability and generalizability of existing CEA results by suggesting adjustments relevant to developing countries.
PIH14 ECONOMIC EVALUATION OF ATOSIBAN VERSUS BETA-MIMETICS IN THE TREATMENT OF PRETERM LABOUR IN GERMANY
Wex J 1 , Connolly MP 2 , Schneider D 2 1 PharmArchitecture Limited, London, UK, 2 Ferring International Center, Saint-Prex, Switzerland OBJECTIVE: Treatment of preterm labour constitutes considerable inpatient cost, and use of tocolytics is central in delaying birth to allow neonatal lungs to mature. The study aimed to compare cost implications of adverse events following tocolysis with atosiban and beta-mimetics. METHODS: Major literature databases were systematically searched to identify randomised clinical trials comparing atosiban with beta-mimetics during the initial 48 h of hospitalisation. Adverse events data from three double blind trials were included in a meta-analysis. Clinical resource use was determined based on routine practice in a regional German hospital. Cost of drug treatment was calculated based on trial protocols and German hospital drug purchase costs; analysis was performed for fenoterol, the only betamimetic licensed in Germany for tocolysis. Costs per case were calculated with G-DRG Grouper. Costs were expressed in €2007. RESULTS: Use of atosiban was associated with significantly lower frequency of adverse events compared to beta-mimetics. From the payer's perspective, cost-saving from using atosiban versus fenoterol was €423 per patient starting treatment. From the hospital's perspective, savings from using atosiban versus continuous fenoterol ranged from €259 for 18 hours of tocolysis to €105 for 48 hours; the respective values for bolus fenoterol were €244 and €55. From the combined perspective, using atosiban versus continuous fenoterol saved from €226 for 18 hours of tocolysis to €71 for 48 hours; versus bolus fenoterol the results were €211 and €21, respectively. In the probabilistic sensitivity analysis atosiban was cost-saving versus both continuous and bolus fenoterol in 100% of iterations at 18 hours and in at least 87% of iterations at 48 hours. CONCLUSION: Atosiban was cost-saving versus beta-mimetics in the treatment of preterm labour in Germany from the payer's, hospital's and combined perspectives. The results were robust in the probabilistic sensitivity analysis. 
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